Table 1.
Demographic and clinical characteristics of colorectal cancer patients.
| Characteristics | Distant metastasis-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|
| n (%)* | n of events* | HR (95% CI) | P | n (%)* | n of events* | HR (95% CI) | P | |
| All patients | 233 | 30 | 282 | 92 | ||||
| Age, years | ||||||||
| Median (IQR) | 66 (56-73) | 65 (54-73) | ||||||
| <65 | 106 (45.5) | 19 | 1.00 | 133 (47.2) | 42 | 1.00 | ||
| ≥65 | 127 (54.5) | 11 | 0.48 (0.23-1.00) | 0.049 | 149 (52.8) | 50 | 1.09 (0.72-1.64) | 0.692 |
| Gender | ||||||||
| Male | 119 (51.1) | 17 | 1.00 | 148 (52.5) | 57 | 1.00 | ||
| Female | 114 (48.9) | 13 | 0.78 (0.38-1.61) | 0.508 | 134 (47.5) | 35 | 0.65 (0.43-0.99) | 0.045 |
| CEA, μg/L | ||||||||
| Median (IQR) | 3.5 (1.7-10.2) | 4.4 (2.0-14.9) | ||||||
| <5 | 129 (59.7) | 14 | 1.00 | 136 (52.3) | 23 | 1.00 | ||
| ≥5 | 87 (40.3) | 15 | 1.61 (0.78-3.34) | 0.198 | 124 (47.7) | 58 | 3.35 (2.07-5.44) | <0.001 |
| Differentiation | ||||||||
| Well | 43 (20.0) | 5 | 1.00 | 51 (19.4) | 11 | 1.00 | ||
| Moderate | 153 (70.8) | 17 | 0.95 (0.35-2.56) | 0.912 | 185 (70.3) | 62 | 1.64 (0.86-3.12) | 0.131 |
| Poor | 19 (9.2) | 6 | 3.17 (0.97-10.4) | 0.057 | 27 (10.3) | 15 | 3.59 (1.65-7.83) | 0.001 |
| Stage† | ||||||||
| I-II | 150 (64.7) | 12 | 1.00 | - | ||||
| III | 82 (35.3) | 18 | 2.92 (1.41-6.06) | 0.004 | - | |||
| I-III | - | 232 (82.6) | 54 | 1.00 | ||||
| IV | - | 49 (17.4) | 38 | 5.19 (3.40-7.92) | <0.001 | |||
| Lymphovascular invasion | ||||||||
| Negative | 179 (76.8) | 14 | 1.00 | 201 (71.3) | 48 | 1.00 | ||
| Positive | 54 (23.2) | 16 | 4.13 (2.02-8.47) | <0.001 | 81 (28.7) | 44 | 2.78 (1.84-4.19) | <0.001 |
| Perineural invasion | ||||||||
| Negative | 202 (86.7) | 23 | 1.00 | 234 (83.0) | 65 | 1.00 | ||
| Positive | 31 (13.3) | 7 | 2.01 (0.86-4.67) | 0.107 | 48 (17.0) | 27 | 2.39 (1.53-3.75) | <0.001 |
| Lymph node involvement | ||||||||
| Negative | 143 (64.1) | 10 | 1.00 | 154 (56.8) | 33 | 1.00 | ||
| Positive | 80 (35.9) | 17 | 3.24 (1.48-7.08) | 0.003 | 117 (43.2) | 56 | 2.76 (1.79-4.24) | <0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; IQR, interquartile range. *Column subtotals do not sum to n of patients and n of events due to missing data.†According to the American Joint Committee on Cancer - Cancer Staging Manual (version 6.0). P ≤ 0.05 are in boldface.